原发性甲状旁腺功能亢进症中[11C]蛋氨酸PET、[11C]胆碱PET与四维CT作为二线扫描检测甲状旁腺腺瘤的头对头比较
这项前瞻性盲法队列研究纳入32例生化确诊原发性甲状旁腺功能亢进症且一线影像阴性或不一致的患者,头对头比较[11C]蛋氨酸PET/CT、[11C]胆碱PET/CT与四维CT。盲法评估中[11C]胆碱PET/CT病灶水平灵敏度85%,显著高于[11C]蛋氨酸PET/CT的67%和四维CT的39%。
要点
- [11C]胆碱PET/CT病灶水平灵敏度85%,[11C]蛋氨酸PET/CT为67%,四维CT为39%。
- [11C]胆碱PET/CT灵敏度显著高于[11C]蛋氨酸PET/CT(p=0.031)和四维CT(p<0.0005)。
- 盲法评估中[11C]胆碱PET/CT阳性28例(88%),[11C]蛋氨酸PET/CT阳性23例(72%),四维CT阳性15例(47%)。
核心结论
- 在原发性甲状旁腺功能亢进症且一线影像阴性的情况下,[11C]胆碱PET/CT在定位甲状旁腺腺瘤方面优于[11C]蛋氨酸PET/CT和四维CT,可使85%的腺瘤获得正确定位。
- 需要进一步研究以确定这些扫描的成本效益和效能,包括将其作为一线或二线影像技术的时机。
研究设计与样本
- 前瞻性、盲法、效能检验的队列研究,纳入32例生化确诊原发性甲状旁腺功能亢进症且既往一线影像(超声和99mTc-甲氧基异丁基异腈)阴性或不一致的患者。
- 所有患者均接受[11C]蛋氨酸PET/CT、[11C]胆碱PET/CT和四维CT检查,先由对患者数据和所有影像结果不知情的核医学科医生和放射科医生盲法判读,再进行非盲法判读。
- 扫描结果与手术和病理组织学发现进行关联,术后至少6个月的血清钙值作为治愈甲状旁腺功能亢进症的金标准。
主要发现
- 盲法评估中,[11C]胆碱PET/CT阳性28例(88%),[11C]蛋氨酸PET/CT阳性23例(72%),四维CT阳性15例(47%)。
- 共30例患者接受手术,32个甲状旁腺病灶经组织学证实为甲状旁腺腺瘤。
- 基于盲法评估,[11C]胆碱PET/CT、[11C]蛋氨酸PET/CT和四维CT的病灶水平灵敏度分别为85%、67%和39%。
- [11C]胆碱PET/CT的灵敏度与[11C]蛋氨酸PET/CT和四维CT的差异均具有统计学意义(分别为p=0.031和p<0.0005)。
关键数值与推荐
- 盲法评估病灶水平灵敏度:[11C]胆碱PET/CT 85%,[11C]蛋氨酸PET/CT 67%,四维CT 39%。
- [11C]胆碱PET/CT与[11C]蛋氨酸PET/CT灵敏度比较p=0.031,与四维CT比较p<0.0005。
临床怎么用
- 作者认为,在原发性甲状旁腺功能亢进症且一线影像阴性的情况下,[11C]胆碱PET/CT在定位甲状旁腺腺瘤方面优于[11C]蛋氨酸PET/CT和四维CT。
局限性
- 需要进一步研究以确定这些扫描的成本效益和效能,包括将其作为一线或二线影像技术的时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate preoperative localization is imperative to guide surgery in primary hyperparathyroidism (pHPT). It remains unclear which second-line imaging technique is most effective after negative first-line imaging. In this study, we compare the diagnostic effectiveness of [11C]methionine PET/CT, [11C]choline PET/CT, and four dimensional (4D)-CT head-to-head in patients with pHPT, to explore which of these imaging techniques to use as a second-line scan. METHODS: We conducted a powered, prospective, blinded cohort study in patients with biochemically proven pHPT and prior negative or discordant first-line imaging consisting of ultrasonography and 99mTc-sestamibi. All patients underwent [11C]methionine PET/CT, [11C]choline PET/CT, and 4D-CT. At first, all scans were interpreted by a nuclear medicine physician, and a radiologist who were blinded from patient data and all imaging results. Next, a non-blinded scan reading was performed. The scan results were correlated with surgical and histopathological findings. Serum calcium values at least 6 months after surgery were used as gold standard for curation of HPT. RESULTS: A total of 32 patients were included in the study. With blinded evaluation, [11C]choline PET/CT was positive in 28 patients (88%), [11C]methionine PET/CT in 23 (72%), and 4D-CT in 15 patients (47%), respectively. In total, 30 patients have undergone surgery and 32 parathyroid lesions were histologically confirmed as parathyroid adenomas. Based on the blinded evaluation, lesion-based sensitivity of [11C]choline PET/CT, [11C]methionine PET/CT, and 4D-CT was respectively 85%, 67%, and 39%. The sensitivity of [11C]choline PET/CT differed significantly from that of [11C]methionine PET/CT and 4D-CT (p = 0.031 and p < 0.0005, respectively). CONCLUSION: In the setting of pHPT with negative first-line imaging, [11C]choline PET/CT is superior to [11C]methionine PET/CT and 4D-CT in localizing parathyroid adenomas, allowing correct localization in 85% of adenomas. Further studies are needed to determine cost-benefit and efficacy of these scans, including the timing of these scans as first- or second-line imaging techniques.
引用
- Noltes ME, Kruijff S, Appelman APA, et al. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2023. PMID: 37975887. doi:10.1007/s00259-023-06488-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。